117 related articles for article (PubMed ID: 27305306)
1. [Rare differential diagnosis of hyperthyroidism].
Besemer B; Müssig K
Dtsch Med Wochenschr; 2016 Jun; 141(12):889. PubMed ID: 27305306
[TBL] [Abstract][Full Text] [Related]
2. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy.
Min L; Vaidya A; Becker C
Eur J Endocrinol; 2011 Feb; 164(2):303-7. PubMed ID: 21088057
[TBL] [Abstract][Full Text] [Related]
3. [Endocrinologic side effects of oncologic treatment with anti-CTLA-4-antibodies].
Fischli S; Allelein S; Zander T; Henzen C
Dtsch Med Wochenschr; 2014 May; 139(19):996-1000. PubMed ID: 24782152
[TBL] [Abstract][Full Text] [Related]
4. Thyroid dysfunction from antineoplastic agents.
Hamnvik OP; Larsen PR; Marqusee E
J Natl Cancer Inst; 2011 Nov; 103(21):1572-87. PubMed ID: 22010182
[TBL] [Abstract][Full Text] [Related]
5. Interaction of interferon alpha therapy with thyroid function tests in the management of hepatitis C: a case report.
Gill G; Bajwa H; Strouhal P; Buch HN
J Med Case Rep; 2016 Sep; 10(1):253. PubMed ID: 27632981
[TBL] [Abstract][Full Text] [Related]
6. Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report.
Carl D; Grüllich C; Hering S; Schabet M
BMC Res Notes; 2015 Jul; 8():316. PubMed ID: 26209970
[TBL] [Abstract][Full Text] [Related]
7. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
8. Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab.
McElnea E; Ní Mhéalóid A; Moran S; Kelly R; Fulcher T
Orbit; 2014 Dec; 33(6):424-7. PubMed ID: 25207976
[TBL] [Abstract][Full Text] [Related]
9. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
Iyer PC; Cabanillas ME; Waguespack SG; Hu MI; Thosani S; Lavis VR; Busaidy NL; Subudhi SK; Diab A; Dadu R
Thyroid; 2018 Oct; 28(10):1243-1251. PubMed ID: 30132401
[TBL] [Abstract][Full Text] [Related]
10. 5: Diagnosis and management of hyperthyroidism and hypothyroidism.
Topliss DJ; Eastman CJ
Med J Aust; 2004 Feb; 180(4):186-93. PubMed ID: 14960142
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
12. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
[TBL] [Abstract][Full Text] [Related]
13. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies.
Orlov S; Salari F; Kashat L; Walfish PG
J Clin Endocrinol Metab; 2015 May; 100(5):1738-41. PubMed ID: 25751110
[TBL] [Abstract][Full Text] [Related]
14. [Ipilimumab-induced hypophysitis].
Schleder S; Schreml S; Heiss P
Rofo; 2013 Mar; 185(3):268-9. PubMed ID: 23154861
[No Abstract] [Full Text] [Related]
15. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma.
Morganstein DL; Lai Z; Spain L; Diem S; Levine D; Mace C; Gore M; Larkin J
Clin Endocrinol (Oxf); 2017 Apr; 86(4):614-620. PubMed ID: 28028828
[TBL] [Abstract][Full Text] [Related]
16. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.
Barjaktarevic IZ; Qadir N; Suri A; Santamauro JT; Stover D
Chest; 2013 Mar; 143(3):858-861. PubMed ID: 23460165
[TBL] [Abstract][Full Text] [Related]
17. Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy?
Dick J; Enk A; Hassel JC
Dermatology; 2015; 230(1):8-10. PubMed ID: 25531526
[TBL] [Abstract][Full Text] [Related]
18. Peripheral neuropathy associated with ipilimumab: a report of 2 cases.
Thaipisuttikul I; Chapman P; Avila EK
J Immunother; 2015; 38(2):77-9. PubMed ID: 25658617
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.
Mathew M; Tam M; Ott PA; Pavlick AC; Rush SC; Donahue BR; Golfinos JG; Parker EC; Huang PP; Narayana A
Melanoma Res; 2013 Jun; 23(3):191-5. PubMed ID: 23462208
[TBL] [Abstract][Full Text] [Related]
20. Transient hyperthyroidism in patients with lymphocytic thyroiditis.
Gorman CA; Duick DS; Woolner LB; Wahner HW
Mayo Clin Proc; 1978 Jun; 53(6):359-65. PubMed ID: 580628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]